Antimicrobial Stewardship Strategy:
Intravenous to oral conversion

Promoting the use of oral antimicrobial agents instead of intravenous administration when clinically indicated.

Description

This is an overview and not intended to be an all-inclusive summary. As a general principle, patients must be monitored by the health care team after changes to therapy resulting from recommendations made by the antimicrobial stewardship team.

Intravenous to oral conversion (IV to PO) involves a policy or guideline for switching the route of administration after careful patient assessment.

Rationale

This strategy has numerous benefits for patients and results in lower health care costs, so it is highly encouraged. Still, studies have shown that antimicrobials with high bioavailability are given intravenously to patients who could tolerate oral intake nearly 50 per cent of the time.¹

Antimicrobials that have high bioavailability and are available in both intravenous and oral formulations (e.g., fluoroquinolones, linezolid, cotrimoxazole, fluconazole) are prime candidates for an IV to PO conversion program and should be given orally if the patient has a functioning gastrointestinal tract, because in such cases there is no advantage to IV administration.

Other antimicrobials can be switched to oral agents that have similar activity (e.g., cefazolin to cephalexin) when the patient’s clinical condition has improved according to predefined criteria (e.g., afebrile, white blood cells normalizing, gastrointestinal tract functioning).

A switch to an oral agent can also occur in conjunction with de-escalation, based on susceptibility results (see De-escalation and streamlining).

This is a PHO CORE strategy

Priority Level:  A
Difficulty Level:  1

Program Stage:
✓ Early
• Intermediate
• Advanced

Antimicrobial Stewardship Outcomes:
• Drug utilization outcomes
• Clinical outcomes

For more information on these criteria and how they were developed, please see the Antimicrobial Stewardship Strategy Criteria Reference Guide.
Implementation

There are several ways to encourage the use of oral agents when possible:

- Policies and guidelines to switch to an appropriate oral agent automatically when certain criteria are met. These automatic substitution policies usually pertain to highly bioavailable agents.
- Transitioning to oral therapy may be performed in consultation with the prescriber when patients meet specific clinical parameters.
- Chart reminders may be used to remind the prescriber once a patient meets specific criteria.
- Many institutions have identified ways to flag patients who may be candidates for IV to PO conversion for review. This may include a manual review of patient profiles by clinical pharmacists via reports generated by pharmacy computer systems or clinical decision support systems.
- Pharmacy and therapeutics committee approval would be required for formalized and/or criteria-based programs if they are pharmacist or nurse-led.

Advantages

- Many potential benefits, including reductions in adverse effects related to the intravenous catheter (e.g., infection, thrombus formation), health care worker workload, patient length of stay, and hospital costs.\(^1\)\(^2\)
- Most infectious-disease guidelines (e.g., community acquired pneumonia, skin and soft tissue infections, urinary tract infections, intra-abdominal infections, etc.) include recommendations for switching to oral antimicrobials once the patient has stabilized.
- IV to PO conversion programs may be initiated or performed by pharmacists or other health care workers based on predetermined clinical criteria.
- When done according to predetermined criteria, this strategy does not compromise patient outcomes.
- Preferential use of the oral route for antimicrobial agents with high bioavailability is a focus of the Association of Medical Microbiology and Infectious Disease Canada/Choosing Wisely Canada program recommendations.\(^3\)

Disadvantages

- May encounter physician or nurse reluctance/reservations, even if criteria are met.
- Requires pharmacy (or other) staff to review antimicrobial orders and assess suitability for oral treatment.
- Could encourage unnecessarily prolonged courses of antimicrobials if the patient is switched to oral agents at or near completion of a treatment course and the stop date is inappropriately extended.

Requirements

- Staff to develop policy, procedures and/or guidelines for formalized programs/initiatives.
- Staff resources to perform conversion.
- Computer software or other methods of identifying patients on IV antimicrobials targeted for possible conversion.
Associated Metrics

- Drug costs, utilization and/or duration of intravenous therapy for targeted antimicrobials.
- Trends in the ratio of IV to PO antimicrobial use for targeted antimicrobials.
- Number of accepted/rejected recommendations for the IV to PO switch.

References


Additional Useful References

Select articles to provide supplemental information and insight into the strategy described and/or examples of how the strategy was applied; not a comprehensive reference list. URLs are provided when materials are freely available on the Internet.


  Excellent instructional paper outlining key considerations for use of oral drugs, including antimicrobials. (An updated chapter has been published but is not publically available).


  Reviews the principles of sequential (IV to PO) therapy and its application in selected infections.

  Improved the timeliness of the IV to PO switch and decreased the duration of IV therapy with a pharmacist-led initiative using guidelines and clinical criteria to recommend changing route of administration.


  A pharmacist-led IV to PO program involving specific criteria and chart reminders that demonstrated reductions in IV antimicrobial use and costs.

Samples/Examples

• Example 1: Markham Stouffville Hospital Corporation - Pharmacist-initiated IV to PO Conversion Program of Antimicrobials
• Example 2: The Ottawa Hospital - Pharmacist-initiated Intravenous (IV) to Oral (PO) Automatic Substitution for Antimicrobial Agents
• Example 3: Alberta Health Services Antimicrobial Stewardship Backgrounder - Intravenous to Oral Antimicrobial Therapy Conversion

These documents have been generously shared by various health care institutions to help others develop and build their antimicrobial stewardship programs. We recommend crediting an institution when adopting a specific tool/form/pathway in its original form.

Examples that contain clinical or therapeutic recommendations may not necessarily be consistent with published guidelines, or be appropriate or directly applicable to other institutions. All examples should be considered in the context of the institution’s population, setting and local antibiogram.

The materials and information in this section are not owned by Public Health Ontario. Neither Public Health Ontario nor the institution sharing the document shall be responsible for the use of any tools and resources by a third party.

Links with Other Strategies

• Checklists
• De-escalation and streamlining
• Disease-specific treatment guidelines, pathways, algorithms and/or associated order forms
• Prospective audit with intervention and feedback
• Scheduled antimicrobial reassessments (“antibiotic time outs”)
Disclaimer

This document may be freely used without permission for non-commercial purposes only and provided that appropriate credit is given to Public Health Ontario. No changes and/or modifications may be made to the content without explicit written permission from Public Health Ontario.

Citation


©Queen’s Printer for Ontario, 2016

For further information


Email: asp@oahpp.ca

Public Health Ontario acknowledges the financial support of the Ontario Government.
Example 1: Markham Stouffville Hospital Corporation - Pharmacist-initiated IV to PO Conversion Program of Antimicrobials

INTERDISCIPLINARY MANUAL

AUTHOR: Director of Pharmacy

FOLDER: Medication Guidelines & Protocols

APPROVED BY: DTC

REVIEW FREQUENCY: 3 years

RESPONSIBILITY: Director of Pharmacy

ORIGINAL APPROVAL DATE: 14/11/02

REVISED/REVIEWED DATE: 18/12/08

05/04/12

290.914.916.010 PHARMACIST-INITIATED IV TO PO CONVERSION PROGRAM OF ANTIMICROBIALS

POLICY:

Early conversion from intravenous (IV) to oral (PO) antimicrobials therapy is effective for a variety of infections. Many oral antimicrobials now have available excellent bioavailability. Conversion from IV to PO antimicrobials therapy in selected patients is an effective way of achieving cost savings for the Hospital (drug costs and nursing/pharmacy labour costs) while aiming for a positive clinical outcome. The switch to oral therapy must be individualized based upon the patient's clinical status and infection.

EXPECTED OUTCOME:

Pharmacists will monitor patients receiving IV antimicrobials, determine their eligibility for conversion to oral treatment, and initiate where appropriate the conversion from IV to PO therapy. The conversion will be documented in the patient’s electronic record and on the Doctor’s Orders sheets. All conversions will be followed to monitor clinical and pharmaco-economic outcomes. (See examples in Appendix A - Suggested Antimicrobial Conversion Table)

PROCEDURE/GUIDELINE:

The inclusion criteria for the pharmacist-initiated automatic conversion program include:

Disclaimer

This resource was created by Markham Stouffville Hospital Corporation. PHO is not the owner of this content and does not take responsibility for the information provided within this document. Neither PHO nor Markham Stouffville Hospital Corporation shall be responsible for the subsequent use of any tools and resources by any third party.
Example 1: Markham Stouffville Hospital Corporation - Pharmacist-initiated IV to PO Conversion Program of Antimicrobials (continued)

- The patient has received 48 hours of IV antimicrobials.
- The patient is improving clinically (i.e. afebrile for at least 24 hours, leukocytes normalizing, hemodynamically stable, and not septic).
- The patient has a functional GI tract, is able to take oral or NG nutrition and/or medications and there is no evidence of malabsorption.
- The pathogen is not known to be resistant to the antimicrobial to be used.
- The patient does not fall under the parameters of exclusion (see below)

Patients should NOT be switched to oral therapy if they meet any of the following exclusion criteria:

- The patient is being treated for an infection where parenteral therapy is indicated, such as Endocarditis, CNS infection (e.g. meningitis, encephalitis), *S aureus* or *Enterococcus* spp. Bacteremia.
- The patient may have an unreliable response to oral therapy due to continuous NG suction, malabsorption syndrome, ileus, protracted vomiting, severe diarrhea.
- The patient is ≤18 years (i.e. Pediatrics).

Disclaimer

This resource was created by Markham Stouffville Hospital Corporation. PHO is not the owner of this content and does not take responsibility for the information provided within this document. Neither PHO nor Markham Stouffville Hospital Corporation shall be responsible for the subsequent use of any tools and resources by any third party.
**Example 1: Markham Stouffville Hospital Corporation - Pharmacist-initiated IV to PO Conversion Program of Antimicrobials (continued)**

### Appendix A - Suggested Antimicrobial Conversion Table

<table>
<thead>
<tr>
<th>IV Drug</th>
<th>Oral Drug</th>
<th>Cost Savings/Day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acyclovir 300 mg (5 mg/kg) q8h</td>
<td>Acyclovir 400 mg q8h OR Valacyclovir 500 mg q12h</td>
<td>$21.33 - $22.22</td>
</tr>
<tr>
<td>Ampicillin 1g q6h</td>
<td>Amoxicillin 500 mg q8h</td>
<td>$7.02</td>
</tr>
<tr>
<td>Azithromycin 500 mg q24h</td>
<td>Azithromycin 250 mg q24h</td>
<td>$18.67</td>
</tr>
<tr>
<td>Cefazolin 1g q8h</td>
<td>Cephalaxin 500 mg q6h</td>
<td>$6.80</td>
</tr>
<tr>
<td>Cefuroxime 750 mg q8h</td>
<td>Cefuroxime Axetil 500 mg q12h</td>
<td>$9.84</td>
</tr>
<tr>
<td>Cefazidime 2g q6h</td>
<td>Ciprofloxacin 750 mg q12h</td>
<td>$21.39</td>
</tr>
<tr>
<td>Ceftriaxone 1g q24h</td>
<td>Ciprofloxacin 500 mg q12h +/- Cephalaxin 500 mg q6h</td>
<td>$4.91 - $5.49</td>
</tr>
<tr>
<td>Ciprofloxacin 400 mg q12h</td>
<td>Ciprofloxacin 500-750 mg q12h</td>
<td>$1.23 - $1.68</td>
</tr>
<tr>
<td>Clindamycin 600 mg q8h</td>
<td>Clindamycin 300 mg q6h</td>
<td>$8.65</td>
</tr>
<tr>
<td>Cloxacillin 1g q6h</td>
<td>Cloxacillin 500 mg q6h</td>
<td>$14.86</td>
</tr>
<tr>
<td>Fluconazole 200 mg q24h</td>
<td>Fluconazole 200 mg q24h</td>
<td>$5.52</td>
</tr>
<tr>
<td>Gentamicin 300 mg (5 mg/kg) q24h</td>
<td>Ciprofloxacin 500 mg q12h OR Trimethoprim/Sulfamethoxazole (SEPTRA) 1 DS q12h</td>
<td>$9.78 - $10.02</td>
</tr>
<tr>
<td>Meropenem 500 mg q6h</td>
<td>Ciprofloxacin 500-750 mg q12h</td>
<td>$95.67 - $96.12</td>
</tr>
<tr>
<td>Metronidazole 500 mg q12h</td>
<td>Metronidazole 500 mg q12h</td>
<td>$1.80</td>
</tr>
<tr>
<td>Moxifloxacin 400 mg q24h</td>
<td>Moxifloxacin 400 mg q24h</td>
<td>$31.02</td>
</tr>
<tr>
<td>Penicillin sodium 4 million units q6h</td>
<td>Penicillin VK 300 mg q6h</td>
<td>$8.89</td>
</tr>
<tr>
<td>Piperacillin/Tazobactam 4.5 g q8h</td>
<td>Amoxicillin/clavulanate 500/125 mg q8h OR Ciprofloxacin 500-750 mg q12h</td>
<td>$26.02 - $26.29</td>
</tr>
<tr>
<td></td>
<td>Ciprofloxacin 500-750 mg q12h</td>
<td>$25.84 - $26.29</td>
</tr>
<tr>
<td></td>
<td>Ciprofloxacin 500-750 mg q12h</td>
<td>$24.88 - $25.33</td>
</tr>
<tr>
<td>Tobramycin 300 mg (5 mg/kg) q24h</td>
<td>Ciprofloxacin 750 mg q12h (for <em>Pseudomonas spp</em>)</td>
<td>$6.77</td>
</tr>
<tr>
<td>Trimethoprim/Sulfamethoxazole (SEPTRA) 10 mL q6h</td>
<td>Trimethoprim/Sulfamethoxazole (SEPTRA) 1 DS q12h</td>
<td>$47.76</td>
</tr>
<tr>
<td>Voriconazole 200 mg (4mg/kg) q12h</td>
<td>Voriconazole 200 mg q12h</td>
<td>$45.00</td>
</tr>
</tbody>
</table>

**Disclaimer**

This resource was created by Markham Stouffville Hospital Corporation. PHO is not the owner of this content and does not take responsibility for the information provided within this document. Neither PHO nor Markham Stouffville Hospital Corporation shall be responsible for the subsequent use of any tools and resources by any third party.
Example 2: The Ottawa Hospital - Pharmacist-initiated Intravenous (IV) to Oral (PO) Automatic Substitution for Antimicrobial Agents

An automatic substitution policy has been endorsed by the Pharmacy and Therapeutics Committee and Medical Advisory Committee to authorize pharmacists at The Ottawa Hospital to change certain antimicrobials administered via the intravenous route to an oral route at an equivalent dose, provided the criteria outlined below are met.

This applies to adult patients prescribed the following agents.

<table>
<thead>
<tr>
<th>Antimicrobial agent</th>
<th>Conversion ratio IV:PO</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azithromycin</td>
<td>1:1</td>
<td>500 mg IV</td>
</tr>
<tr>
<td>Ciprofloxacin**</td>
<td>1:1-2.5:1.88</td>
<td>400 mg IV</td>
</tr>
<tr>
<td>Flucloxacillin**</td>
<td>1:1</td>
<td>200 mg IV</td>
</tr>
<tr>
<td>Levofloxacin**</td>
<td>1:1</td>
<td>750 mg IV</td>
</tr>
<tr>
<td>Linezolid</td>
<td>1:1</td>
<td>600 mg IV</td>
</tr>
<tr>
<td>Metronidazole**</td>
<td>1:1</td>
<td>500 mg IV</td>
</tr>
<tr>
<td>Trimethoprim-sulfamethoxazole</td>
<td>90-100%</td>
<td>20 mL IV</td>
</tr>
</tbody>
</table>

**DS: double strength; F: bioavailability
**: ciprofloxacin should be administered at least 2 hours before or 6 hours after calcium, iron and other cations. Levofloxacin should be administered at least 2 hours before or 2 hours after these cations. Continuous enteral feeds should be held 1 hour before and after each dose of ciprofloxacin or levofloxacin.
†: Do not administer via jejunostomy tube (J-tube) as it bypasses the main site of absorption. Do not use ciprofloxacin suspension with any tube as it may clog them.

The antimicrobial agents listed above should be changed from IV to PO when all 3 of the following criteria are met and when patient’s adherence to therapy is anticipated:

<table>
<thead>
<tr>
<th>1) Improving clinically</th>
<th>2) Able to tolerate and absorb oral medications</th>
<th>3) No exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>This may be indicated by:</td>
<td>Enterally fed or eating or drinking fluid diet, AND</td>
<td>DO NOT change to PO if:</td>
</tr>
<tr>
<td>Consistent improvement in fever over the last 24 hours or the patient is afebrile (&lt;38°C)</td>
<td>Taking other medications orally, AND</td>
<td>Meningitis, severe sepsis, endocarditis</td>
</tr>
<tr>
<td>White blood cells normalizing</td>
<td>No severe or persistent nausea, vomiting or diarrhea, AND</td>
<td>Order for NPO in chart</td>
</tr>
<tr>
<td>The patient should also be hemodynamically stable.</td>
<td>No gastrointestinal obstruction, ileus, malabsorption syndrome, active gastrointestinal bleed, or continuous gastric suctioning</td>
<td>Acute treatment phase of infections listed below (discuss with attending team or consult Infectious Diseases):</td>
</tr>
</tbody>
</table>

Disclaimer

This resource was created by The Ottawa Hospital. PHO is not the owner of this content and does not take responsibility for the information provided within this document. Neither PHO nor The Ottawa Hospital shall be responsible for the subsequent use of any tools and resources by any third party.
Example 3: Alberta Health Services Antimicrobial Stewardship Backgrounder - Intravenous to Oral Antimicrobial Therapy Conversion

Intravenous to Oral Antimicrobial Therapy Conversion

**BOTTOM LINE:** Converting patients’ antimicrobial therapy from intravenous (IV) to oral (PO) administration has many patient and health system advantages including:

- Shortened length of hospital stay
- Reduced risk of line-related infection and adverse events
- No IV related mobility restrictions for patients
- Decreased costs (e.g., medication preparation and administration time, IV supplies, drug costs)

IV to PO conversion is a simple but important antimicrobial stewardship strategy.

**Two categories of antimicrobial therapy conversions:**

1. **Switch therapy:** Oral antimicrobial has rapid absorption and excellent oral bioavailability. Systemic exposure is comparable for oral and intravenous routes thus no advantage of IV over PO.
   - Use oral therapy unless patient has oral absorption issues
     - Initial oral therapy is appropriate (i.e., IV therapy does not have to be used initially)

2. **Step down therapy:** Systemic exposure is not equivalent for oral and intravenous routes.
   - Converting therapy from IV to PO route requires individual patient assessment
   - IV therapy can be switched to oral therapy once a patient is stable with improving clinical status (e.g., white blood cell count, temperature, respiratory rate) and no oral absorption issues

**Conditions that can result in potential oral absorption issues:**

- Shock
- Severe or persistent nausea/vomiting/diarrhea
- Active gastrointestinal (GI) bleeding
- Documented ileus or GI obstruction
- Shortened GI transit time (e.g., malabsorption syndromes, removal of part of GI tract, inflammatory bowel disease)
- Continuous tube feeding/nasogastric suctioning that cannot be interrupted for medication administration
- Drug interactions that would limit oral antimicrobial absorption

**Did you know...**

AHS has IV to PO therapeutic interchanges for ciprofloxacin, clindamycin, levofloxacin, and metronidazole. See on-line provincial drug formulary for details.

References:


Prepared by: Jenna Eisbrenner BScPharm, PharmD candidate
Reviewed by: John Conly, MD, FRCPC, Co-chair Antimicrobial Stewardship Committee, AHS & Susan Fryters, BScPharm, ACPR, Antimicrobial Utilization/ID Pharmacist, Edmonton Zone & Micheal Guignis, BScPharm, Ph D, Drug Stewardship Pharmacist, Edmonton Zone


Disclaimer

This resource was created by Alberta Health Services. PHO is not the owner of this content and does not take responsibility for the information provided within this document. Neither PHO nor Alberta Health Services shall be responsible for the subsequent use of any tools and resources by any third party.
### Antimicrobial Stewardship Backgrounder

#### IV to PO Conversion Recommendations

<table>
<thead>
<tr>
<th>Parenteral Therapy</th>
<th>Cost ($/Day)</th>
<th>Oral Therapy</th>
<th>Cost ($/Day)</th>
<th>Oral Bioavailability (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ciprofloxacin 200-400 mg q12h</td>
<td>$3.24 – 4.94</td>
<td>Ciprofloxacin 500-750 mg q12h</td>
<td>$0.32 – 0.35</td>
<td>70</td>
</tr>
<tr>
<td>Cindamycin 600 mg q8h</td>
<td>$25.99</td>
<td>Cindamycin 300-450 mg q8h</td>
<td>$0.73 – 1.10</td>
<td>90</td>
</tr>
<tr>
<td>Fluconazole 400 mg daily</td>
<td>$14.87</td>
<td>Fluconazole 400 mg daily</td>
<td>$2.88</td>
<td>90</td>
</tr>
<tr>
<td>Levofloxacin 250-750 mg daily</td>
<td>$4.86 – 13.59</td>
<td>Levofloxacin 250-750 mg daily</td>
<td>$0.11 – 0.34</td>
<td>99</td>
</tr>
<tr>
<td>Linezolid 600 mg q12h</td>
<td>$195.04</td>
<td>Linezolid 600 mg q12h</td>
<td>$144.25</td>
<td>100</td>
</tr>
<tr>
<td>Metronidazole 500 mg q12h</td>
<td>$3.38</td>
<td>Metronidazole* 500 mg q12h</td>
<td>$0.25</td>
<td>100</td>
</tr>
<tr>
<td>Moxifloxacin 400 mg daily</td>
<td>$17.51</td>
<td>Moxifloxacin 400 mg daily</td>
<td>$4.00</td>
<td>90</td>
</tr>
<tr>
<td>Trimethoprim-sulfamethoxazole 160/800 mg q8h</td>
<td>$38.60</td>
<td>Trimethoprim-sulfamethoxazole 1 05 tab q12h</td>
<td>$0.21</td>
<td>85</td>
</tr>
<tr>
<td>Voriconazole 400 mg q12h ± 2 doses then 200 mg q12h</td>
<td>$571.80</td>
<td>Voriconazole 400 mg q12h ± 2 doses then 200 mg q12h</td>
<td>$41.54</td>
<td>96</td>
</tr>
</tbody>
</table>

* Includes toxic megacolon
a) Usual adult dose with normal renal and hepatic function
b) Inpatient drug costs. Parenteral therapy cost does not include the costs of IV administration or supplies

#### Step down Therapy

<table>
<thead>
<tr>
<th>Parenteral Therapy</th>
<th>Cost ($/Day)</th>
<th>Oral Therapy</th>
<th>Cost ($/Day)</th>
<th>Oral Bioavailability (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amoxicillin 1-2 g q8h</td>
<td>$18.00 – 36.00</td>
<td>Amoxicillin 500 mg q6h</td>
<td>$0.19</td>
<td>80</td>
</tr>
<tr>
<td>Azithromycin 500 mg daily</td>
<td>$8.32</td>
<td>Azithromycin 250 mg daily</td>
<td>$0.64</td>
<td>37**</td>
</tr>
<tr>
<td>Cefazolin 1-2 g q8h</td>
<td>$2.33 – 4.65</td>
<td>Cephalexin*** 500 mg q6h</td>
<td>$0.46</td>
<td>90</td>
</tr>
<tr>
<td>Cefuroxime 0.75 – 1.5 g q8h</td>
<td>$18.24 – 36.48</td>
<td>Cefuroxime axetil 0.5 – 1 g q12h</td>
<td>$1.84 – 3.68</td>
<td>52</td>
</tr>
<tr>
<td>Cefoxitin 1-2 g q8h</td>
<td>$5.18 – 10.36</td>
<td>Cephalexin 500 mg q6h</td>
<td>$0.46</td>
<td>90</td>
</tr>
<tr>
<td>Penicillin G 3.4 million units q8h</td>
<td>$3.31 – 4.42</td>
<td>Penicillin V 300 mg q6h</td>
<td>$0.18</td>
<td>60-73</td>
</tr>
</tbody>
</table>

** Low bioavailability but excellent distribution to tissues.
*** If a pathogen has been identified, ensure organism is susceptible to cephalexin.
a) Usual adult dose with normal renal and hepatic function
b) Inpatient drug costs. Parenteral therapy cost does not include the costs of IV administration or supplies.

Prepared by: Jenna Eisbrenner BScPharm, PharmD candidate
Reviewed by: John Conly, MD, FRCP, Co-chair Antimicrobial Stewardship Committee, AHS & Susan Fryeza, BScPharm, ACPhA, Antimicrobial Utilization/Dt Pharmacist, Edmonton Zone & Michael Guilgul, BSc, Pharm D, Drug Stewardship Pharmacist, Edmonton Zone

Available online from: [http://www.albertahealthservices.ca/assets/Infocfr/hp/if-hp-antimicrobial-asb-issue-3-2014-06.pdf](http://www.albertahealthservices.ca/assets/Infocfr/hp/if-hp-antimicrobial-asb-issue-3-2014-06.pdf)

### Disclaimer

This resource was created by Alberta Health Services. PHO is not the owner of this content and does not take responsibility for the information provided within this document. Neither PHO nor Alberta Health Services shall be responsible for the subsequent use of any tools and resources by any third party.